UNICA IRIS Institutional Research Information System

ONALI, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 64.018
NA - Nord America 3.847
AS - Asia 2.108
SA - Sud America 422
Continente sconosciuto - Info sul continente non disponibili 238
AF - Africa 69
OC - Oceania 10
Totale 70.712
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 63.159
US - Stati Uniti d'America 3.770
SG - Singapore 955
CN - Cina 489
BR - Brasile 322
VN - Vietnam 275
SE - Svezia 261
FI - Finlandia 140
DE - Germania 124
FR - Francia 102
HK - Hong Kong 92
GB - Regno Unito 70
BD - Bangladesh 69
IN - India 46
AR - Argentina 42
CA - Canada 35
MX - Messico 25
KR - Corea 24
PL - Polonia 24
ZA - Sudafrica 24
IQ - Iraq 23
NL - Olanda 21
ES - Italia 19
TR - Turchia 18
RU - Federazione Russa 16
AT - Austria 15
EC - Ecuador 15
ID - Indonesia 14
JP - Giappone 14
SA - Arabia Saudita 14
PK - Pakistan 13
MA - Marocco 12
UZ - Uzbekistan 12
IE - Irlanda 11
CO - Colombia 10
UA - Ucraina 9
CH - Svizzera 8
CL - Cile 8
EG - Egitto 8
PH - Filippine 8
PY - Paraguay 8
KE - Kenya 7
MY - Malesia 7
VE - Venezuela 7
AU - Australia 6
TN - Tunisia 6
CZ - Repubblica Ceca 5
GR - Grecia 5
HU - Ungheria 5
AZ - Azerbaigian 4
BG - Bulgaria 4
BO - Bolivia 4
ET - Etiopia 4
IL - Israele 4
BE - Belgio 3
DZ - Algeria 3
GT - Guatemala 3
IR - Iran 3
JM - Giamaica 3
KZ - Kazakistan 3
LU - Lussemburgo 3
RS - Serbia 3
AL - Albania 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
EU - Europa 2
FJ - Figi 2
GY - Guiana 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
LK - Sri Lanka 2
NP - Nepal 2
NZ - Nuova Zelanda 2
PE - Perù 2
RO - Romania 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
AE - Emirati Arabi Uniti 1
AI - Anguilla 1
AM - Armenia 1
AO - Angola 1
BB - Barbados 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CI - Costa d'Avorio 1
GA - Gabon 1
GE - Georgia 1
HR - Croazia 1
JO - Giordania 1
KH - Cambogia 1
LT - Lituania 1
LV - Lettonia 1
MK - Macedonia 1
NG - Nigeria 1
NI - Nicaragua 1
OM - Oman 1
PA - Panama 1
Totale 70.472
Salva come PNG Salva come JPEG
Città #
Cagliari 60.983
Uta 1.921
Ashburn 585
Singapore 515
San Jose 302
Fairfield 277
Nyköping 204
Dallas 188
Boardman 184
Council Bluffs 134
Seattle 119
Wilmington 116
Helsinki 115
Houston 106
Chandler 105
Woodbridge 104
Cambridge 102
Los Angeles 97
Santa Clara 92
New York 88
Ho Chi Minh City 82
Hong Kong 82
Beijing 70
Lauterbourg 63
Boston 56
Dong Ket 52
Hanoi 46
Redwood City 46
Hefei 41
The Dalles 39
Rome 38
Ann Arbor 35
São Paulo 31
Buffalo 30
Hangzhou 30
Munich 27
Redondo Beach 25
London 23
Frankfurt am Main 22
San Diego 22
Seoul 22
Atlanta 21
Milan 21
Warsaw 20
Chicago 19
Shanghai 19
Orem 18
Montreal 15
Tokyo 14
Turku 14
Jacksonville 13
Belo Horizonte 12
Guangzhou 12
Phoenix 12
San Francisco 12
Stockholm 12
Haiphong 11
Lappeenranta 11
Nuremberg 11
Baghdad 10
Johannesburg 10
Mexico City 10
Tashkent 10
Vienna 10
Da Nang 9
Denver 9
Nanjing 9
Newark 9
Rio de Janeiro 9
Beachwood 8
Chennai 8
Columbus 8
Düsseldorf 8
Elk Grove Village 8
Figino 8
Mountain View 8
Salvador 8
Amsterdam 7
Dublin 7
Madrid 7
Manchester 7
Naples 7
Tianjin 7
Brasília 6
Brooklyn 6
Casablanca 6
Dalian 6
Nairobi 6
Quito 6
Salt Lake City 6
Toronto 6
Turin 6
Wuhan 6
Brno 5
Bắc Ninh 5
Chattanooga 5
Cleveland 5
Columbia 5
Curitiba 5
Jeddah 5
Totale 67.782
Salva come PNG Salva come JPEG
Nome #
IBD Flare in the COVID-19 Pandemic: Therapy Discontinuation Is to Blame 9.056
Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab 2.143
An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors 2.127
Colonic phenotype of the ileum in Crohn's disease: A prospective study before and after ileocolonic resection 1.999
Ileal lesions in patients with ulcerative colitis after ileo-rectal anastomosis: Relationship with colonic metaplasia 1.871
Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease 1.648
Impact of a multidisciplinary approach in enteropathic spondyloarthritis patients 1.594
Response Assessed by Ultrasonography as Target of Biological Treatment for Crohn's Disease 1.591
The Resolution of Intestinal Inflammation: The Peace-Keeper's Perspective 1.554
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 1.550
Steroid-free remission and closure of recto-vaginal fistula using adalimumab in a Crohn's disease patient naïve to anti-tumour necrosis factor alpha antibodies 1.479
Cancer and immunomodulators in inflammatory bowel diseases 1.367
Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease 1.341
A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease 1.335
Adalimumab in active ulcerative colitis: A "real-life" observational study 1.207
Psoriasis phenotype in inflammatory bowel disease: A case-control prospective study 1.202
Small bowel capsule endoscopy vs conventional techniques in patients with symptoms highly compatible with Crohn's Disease 1.200
Tbet Expression in Regulatory T Cells Is Required to Initiate Th1-Mediated Colitis 1.186
Endoscopic vs ultrasonographic findings related to Crohn's Disease recurrence: A prospective longitudinal study at 3 years 1.156
Anti-TNF-alpha treatments and obstructive symptoms in Crohn's Disease: A prospective study 1.123
A novel Smad7 genetic variant mapping on the genomic region targeted by Mongersen is associated with Crohn's disease 1.085
The Italian clinical experience with adalimumab in Crohn's disease: Eleven clinical cases 1.083
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease 1.077
Female reproductive health and inflammatory bowel disease: A practice-based review 1.063
Tumor infiltrating regulatory t cells in sporadic and colitis-associated colorectal cancer: The red little riding hood and the wolf 1.026
Early post-operative endoscopic recurrence in Crohn's disease patients: Data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohort 991
Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy 987
GPR120/FFAR4: A Potential New Therapeutic Target for Inflammatory Bowel Disease 956
Measuring disease activity in Crohn's disease 937
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy 928
Azathioprine for prevention of clinical recurrence in Crohn's disease patients with severe endoscopic recurrence: an IG-IBD randomized double-blind trial 914
Post-operative recurrence of Crohn's disease: A prospective study at 5 years 883
TRAF3IP2 gene is associated with cutaneous extraintestinal manifestations in Inflammatory bowel disease 878
Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology 871
Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 854
A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn’s Disease: A Phase II, Open-Label Study 847
Long-term safety of Infliximab for the treatment of inflammatory bowel disease: Does blocking TNFα reduce colitis-associated colorectal carcinogenesis? 839
Comparative Effectiveness Research: A Roadmap to Sail the Seas of IBD Therapies 829
Laparoscopic versus open ileo-colonic resection in crohn's disease: Short- and long-term results from a prospective longitudinal study 801
Efficacy and safety of infliximab and adalimumab in Crohn's disease: A single centre study 794
Cancer in Crohn's disease patients treated with infliximab: A long-term multicenter matched pair study 777
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study 743
Comparison of two strategies for the management of postoperative recurrence in Crohn's disease patients with one clinical risk factor: A multicentre IG-IBD study 732
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 731
Immune system and gut microbiota senescence in elderly IBD patients 710
Development of a numerical index quantitating small bowel damage as detected by ultrasonography in Crohn's disease 705
A family study of asymptomatic small bowel Crohn's disease 702
Small intestine contrast ultrasonography vs computed tomography enteroclysis for assessing ileal Crohn's disease 685
Fistulizing pattern in Crohn's disease and pancolitis in ulcerative colitis are independent risk factors for cancer: A single-center cohort study 659
Frequency, pattern, and risk factors of postoperative recurrence of Crohn's disease after resection different from ileo-colonic 642
Accuracy of small-intestine contrast ultrasonography, compared with computed tomography enteroclysis, in characterizing lesions in patients with Crohn's disease 640
Wireless capsule endoscopy and proximal small bowel lesions in Crohn's disease 635
Frequency and pattern of endoscopic recurrence in Crohn's disease patients with ileocolonic resection using a laparoscopic versus laparotomic approach: A prospective longitudinal study 594
Non-invasive techniques for assessing postoperative recurrence in Crohn's disease 552
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study 548
Wireless capsule endoscopy and small intestine contrast ultrasonography in recurrence of Crohn's disease 543
Severity of postoperative recurrence in Crohn's disease: Correlation between endoscopic and sonographic findings 483
Multiple Orocutaneous Extraintestinal Manifestations in Ulcerative Colitis Patient: Complete Response to Ustekinumab 467
Telemedicine in inflammatory bowel disease from its origin to the post pandemic golden age: A narrative review 429
Adherence to Mediterranean Diet and Diet Quality in Patients with Inflammatory Bowel Disease: A Single-Center, Observational, Case-Control Study 237
Italian validation of the IBD-disk tool for the assessment of disability in inflammatory bowel diseases: A cross-sectional multicenter study 206
Pragmatic Trial Design to Compare Real-world Effectiveness of Different Treatments for Inflammatory Bowel Diseases: The PRACTICE-IBD European Consensus 188
Eosinophilic esophagitis in the "atopic march": dupilumab as an "umbrella" strategy for multiple coexisting atopic diseases 159
Interplay Between Depression and Inflammatory Bowel Disease: Shared Pathogenetic Mechanisms and Reciprocal Therapeutic Impacts-A Comprehensive Review 152
Suboptimal disease control and contributing factors in Italian IBD patients: The IBD-PODCAST Study 142
Xanthine Oxidase-Dependent Activation of NLPR3 Inflammasome in Epithelial Cells Sustains Inflammation in Inflammatory Bowel Disease 130
Patient Satisfaction with IBD Undergoing Colonoscopy: A Multicenter Cross-Sectional Study 125
Patients with Crohn’s Disease Achieving Ustekinumab-Induced Remission Are Characterized by Increased Baseline IL-23 Receptor Expression on Lamina Propria Th1 Cells 123
Adaptation of the European Crohn's Colitis Organisation quality of care standards to Italy: The Italian Group for the study of inflammatory bowel disease consensus 119
Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning—the IG-IBD LIVE study 103
Real-world Effectiveness of Tofacitinib on Ulcerative Colitis-Associated Spondyloarthropathy: a multicenter prospective study from the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD) 99
Real-life effectiveness and safety of tofacitinib and vedolizumab as 2nd-line for ulcerative colitis after anti-TNFs: A multicenter cohort IGIBD study (VE2TO-UC) 95
Optimizing Malnutrition Risk Detection in Inflammatory Bowel Disease: A Longitudinal Analysis of Serial Nutritional Screening Tools 87
Corrigendum to "Telemedicine in inflammatory bowel disease from its origin to the post pandemic golden age: A narrative review" [Digestive and Liver Disease, Volume 56, Issue 1, January 2024, Pages 1-6] 80
Crohn’s disease and ulcerative colitis patient-reported outcomes signs and symptoms for the remote management of inflammatory bowel disease during the COVID-19 pandemic 80
IBD impact on quality of life and perception of disease activity in Italian patients and physicians: An IBD-PODCAST study sub analysis 62
Sequencing JAK-inhibitors in ulcerative colitis: effectiveness and safety of switching within treatment class 59
Multicenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD Study 51
The role of a multidisciplinary approach in the early and differential diagnosis of inflammatory bowel disease–related spondyloarthritis: insights from a cross-sectional study 29
Ustekinumab and Janus Kinase Inhibitors Outperform Vedolizumab as Second-line Therapy in Anti-tumor Necrosis Factor-experienced Patients With Ulcerative Colitis 21
Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease 16
Totale 70.712
Salva come PNG Salva come JPEG
Categoria #
all - tutte 98.456
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 98.456
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20225.131 0 367 306 237 377 498 188 351 646 570 934 657
2022/20238.657 544 1.071 1.175 529 725 1.276 454 733 461 543 738 408
2023/20247.747 399 352 293 492 633 1.533 953 824 395 528 635 710
2024/202539.273 15.737 12.943 4.297 2.031 939 1.434 1.084 58 225 180 133 212
2025/20265.338 333 167 646 589 342 371 1.112 298 429 516 374 161
2026/2027359 147 212 0 0 0 0 0 0 0 0 0 0
Totale 70.712